Sodium-glucose cotransporter 2 inhibitors: impact on body weight and blood pressure compared with other antidiabetic drugs.

Sodium-glucose cotransporter 2 inhibitors: impact on body weight and blood pressure compared with other antidiabetic drugs.
Cardiovasc Hematol Disord Drug Targets. 2018 Feb 06;:
Authors: Imprialos K, Stavropoulos K, Stavropoulos N, Patoulias D, Petidis K, Grassos C, Dimitriadis K, Tsioufis C
Abstract
BACKGROUND: Sodium-glucose co-transporters 2 inhibitors have emerged as a novel antidiabetic class of drugs offering significant ameliorating effects on a variety of cardiovascular risk factors, secondary to their mechanism of action, including blood pressure and body weight.
OBJECTIVE: The purpose of this article is to discuss available data on the impact of SGLT-2 inhibitors on blood pressure and body weight compared with other available antidiabetic drugs and to present potential mechanisms mediating these effects.
METHODS: O comprehensive review of the literature was performed to identify studies examining the effects of SGLT-2 inhibitors on blood pressure and body weight.
RESULTS: SGLT-2 inhibition has been related with a mild decrease in blood pressure of approximately 3-5mmHg in systolic and 1-2mmHg in diastolic blood pressure. These data have been confirmed with more 24h ambulatory measurements, as well. Furthermore, given the loss of calories in the urine, a mild decrease in body weight is anticipated as well. Studies with this class of drugs noted a reduction in body weight of 2 to 3 kg, similar to the l...

Source: Cardiovascular and Hematological Disorders Drug Targets - February 9, 2018 Category: Drugs & Pharmacology Tags: Cardiovasc Hematol Disord Drug Targets Source Type: research